Form 4: TransMedics Group Director Stephanie Lovell Reports Acquisition of Stock and Stock Options

Director Stephanie Lovell reports acquisition of 732 shares of common stock and 1,154 stock options in TransMedics Group, Inc.

Summary

• On May 23, 2024, Stephanie Lovell, a director of TransMedics Group, Inc., acquired 732 shares of common stock and 1,154 stock options.
• The 732 shares were acquired as restricted stock units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• The stock options have an exercise price of $137.53 and vest in full on the earlier of May 23, 2025, or the date of the 2025 annual meeting of stockholders, subject to continued service.
• Following the transaction, Lovell directly owns 1,925 shares of TransMedics Group, Inc. common stock and 1,154 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the amounts are not substantial enough to indicate a strong bullish signal.

Positives

• The acquisition of stock and stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The acquisition of shares and options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates